Sionna Therapeutics (NASDAQ:SION) Earns Neutral Rating from Wedbush

Sionna Therapeutics (NASDAQ:SION)‘s stock had its “neutral” rating reaffirmed by equities research analysts at Wedbush in a research note issued to investors on Monday, MarketBeat.com reports. They presently have a $5.00 price objective on the stock. Wedbush’s target price would indicate a potential upside of 23.30% from the stock’s current price.

A number of other equities research analysts also recently weighed in on the stock. Raymond James Financial reaffirmed a “strong-buy” rating and set a $59.00 price objective on shares of Sionna Therapeutics in a research report on Thursday. Freedom Capital lowered Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, May 20th. Wall Street Zen cut Sionna Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. JonesTrading raised their price target on Sionna Therapeutics from $52.00 to $63.00 and gave the stock a “buy” rating in a report on Tuesday, April 28th. Finally, Stifel Nicolaus reiterated a “hold” rating and issued a $7.00 target price on shares of Sionna Therapeutics in a research note on Monday. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Sionna Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $42.22.

Sionna Therapeutics Price Performance

Shares of SION stock traded down $46.98 on Monday, hitting $4.05. 23,315,454 shares of the stock traded hands, compared to its average volume of 548,288. The company’s fifty day moving average is $42.35 and its 200 day moving average is $40.42. Sionna Therapeutics has a 1-year low of $4.01 and a 1-year high of $54.97. The company has a market capitalization of $183.33 million, a PE ratio of -1.88 and a beta of 1.32.

Sionna Therapeutics (NASDAQ:SION) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.02). As a group, equities research analysts expect that Sionna Therapeutics will post -2.63 EPS for the current year.

Insider Buying and Selling

In related news, Director Orbimed Advisors Llc sold 85,918 shares of the business’s stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $44.86, for a total transaction of $3,854,281.48. Following the sale, the director owned 2,469,959 shares of the company’s stock, valued at $110,802,360.74. The trade was a 3.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter A. Thompson sold 85,918 shares of the company’s stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $44.86, for a total value of $3,854,281.48. Following the completion of the sale, the director owned 2,469,959 shares of the company’s stock, valued at approximately $110,802,360.74. This trade represents a 3.36% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 403,726 shares of company stock valued at $18,259,354. Company insiders own 5.10% of the company’s stock.

Hedge Funds Weigh In On Sionna Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. acquired a new position in shares of Sionna Therapeutics in the second quarter worth about $64,875,000. Deutsche Bank AG purchased a new stake in shares of Sionna Therapeutics during the second quarter worth $2,347,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in shares of Sionna Therapeutics during the 2nd quarter worth about $44,000. Bank of New York Mellon Corp bought a new stake in Sionna Therapeutics in the second quarter worth approximately $1,829,000. Finally, State of Wyoming bought a new position in shares of Sionna Therapeutics during the 2nd quarter valued at $35,000.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.